DNA Biomed Revenue vs. Price to Book
| DNA Stock | ILS 89.60 1.00 1.10% |
For DNA Biomed profitability analysis, we use financial ratios and fundamental drivers that measure the ability of DNA Biomed to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well DNA Biomed Solns utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between DNA Biomed's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of DNA Biomed Solns over time as well as its relative position and ranking within its peers.
DNA |
DNA Biomed Solns Price to Book vs. Revenue Fundamental Analysis
DNA Revenue vs. Competition
DNA Biomed Solns is currently under evaluation in revenue category among related companies. Market size based on revenue of Information Technology industry is currently estimated at about 1.22 Billion. DNA Biomed adds roughly 0.0 in revenue claiming only tiny portion of equities under Information Technology industry.
DNA Price to Book vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
DNA Biomed |
| = | null |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
DNA Biomed | = | null |
Use DNA Biomed in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if DNA Biomed position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DNA Biomed will appreciate offsetting losses from the drop in the long position's value.DNA Biomed Pair Trading
DNA Biomed Solns Pair Trading Analysis
The ability to find closely correlated positions to DNA Biomed could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace DNA Biomed when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back DNA Biomed - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling DNA Biomed Solns to buy it.
The correlation of DNA Biomed is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as DNA Biomed moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if DNA Biomed Solns moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for DNA Biomed can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your DNA Biomed position
In addition to having DNA Biomed in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Large Cap ETFs Thematic Idea Now
Large Cap ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Large Cap ETFs theme has 560 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Large Cap ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Investing Opportunities. Note that the DNA Biomed Solns information on this page should be used as a complementary analysis to other DNA Biomed's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Complementary Tools for DNA Stock analysis
When running DNA Biomed's price analysis, check to measure DNA Biomed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DNA Biomed is operating at the current time. Most of DNA Biomed's value examination focuses on studying past and present price action to predict the probability of DNA Biomed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DNA Biomed's price. Additionally, you may evaluate how the addition of DNA Biomed to your portfolios can decrease your overall portfolio volatility.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Commodity Directory Find actively traded commodities issued by global exchanges |
To fully project DNA Biomed's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of DNA Biomed Solns at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include DNA Biomed's income statement, its balance sheet, and the statement of cash flows.